FINE-HEART Pooled Analysis
Maria Pabon
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
John Ostrominski
ns-MRAs and eGFR Slope: The Kidney Perspective
Csaba P. Kovesdy, MD
Finnian R. Mc Causland, MD
ns-MRAs: The Cardiovascular-Kidney-Metabolic Connection
Mastering MRA Monitoring: The Key to Success
Akshay S. Desai, MD
John McMurray, MD
Optimizing HF Outcomes Across the Spectrum: Emerging Evidence
Strategies for managing hyperkalemia in cardiorenal disease: A clinical dialogue defining a roadmap to improved outcomes
Gianluigi Savarese, MD
James Burton, DM, FRCP
Aaron Wong, MD
A multidisciplinary clinical dialogue: Optimizing long-term goals: practical approaches to novel potassium binder use in cardiorenal care
Summarizing multidisciplinary strategies: Where do we go from here?
Challenges of managing hyperkalemia in HF patients with CKD while maintaining RAAS inhibitor therapy
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC
Scott Solomon, MD
Mikhail Kosiborod, MD
Nonsteroidal MRAs: The CKD/T2D Advantage
Pardeep Jhund, MD, PhD
Nonsteroidal MRAs: The CKD/T1D Potential
Hiddo L. Heerspink, PhD
Bridging the Gap: ns-MRAs in Cardiovascular-Kidney-Metabolic Syndrome Care
Orly Vardeny, MD
Muthiah Vaduganathan, MD, MPH
MOA Deep Dive: The MRA Spectrum
Emerging Evidence in HF Care
Loading...
We're glad to see you're enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.